Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial
暂无分享，去创建一个
H. Dombret | D. Olive | S. Leprêtre | A. Delannoy | B. Quesnel | C. Preudhomme | A. Toubert | C. Gardin | X. Thomas | G. Guillerm | C. Récher | N. Ifrah | N. Vey | P. Rousselot | N. Dulphy | E. Jourdan | E. Raffoux | A. Pigneux | C. Pautas | J. Marolleau | R. Zerbib | J. Malfuson | M. Hunault | B. Lioure | C. Paturel | Y. Hicheri | P. Dumas | C. Bonmati | C. Bulabois | S. Castaigne | M. Ojeda | L. Gastaud | J. Bouhris | P. André | Lucile Beautier